Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 17 10:23AM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-0.95 Insider Own61.38% Shs Outstand40.10M Perf Week-1.38%
Market Cap479.36M Forward P/E- EPS next Y-1.69 Insider Trans-0.13% Shs Float15.73M Perf Month30.40%
Income-30.82M PEG- EPS next Q-0.31 Inst Own43.18% Short Float4.34% Perf Quarter15.33%
Sales0.00M P/S- EPS this Y-68.92% Inst Trans- Short Ratio5.19 Perf Half Y63.54%
Book/sh6.71 P/B1.75 EPS next Y-28.37% ROA-10.70% Short Interest0.68M Perf Year161.67%
Cash/sh6.61 P/C1.78 EPS next 5Y- ROE-11.05% 52W Range4.06 - 12.42 Perf YTD7.34%
Dividend Est.- P/FCF- EPS past 5Y- ROI-11.32% 52W High-5.19% Beta2.85
Dividend TTM- Quick Ratio50.29 Sales past 5Y0.00% Gross Margin- 52W Low190.02% ATR (14)0.72
Dividend Ex-Date- Current Ratio50.29 EPS Y/Y TTM-5.40% Oper. Margin0.00% RSI (14)66.55 Volatility7.88% 7.32%
Employees30 Debt/Eq0.01 Sales Y/Y TTM- Profit Margin- Recom2.00 Target Price9.55
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q41.33% Payout- Rel Volume0.45 Prev Close11.59
Sales Surprise- EPS Surprise44.90% Sales Q/Q- EarningsMar 26 BMO Avg Volume131.53K Price11.77
SMA2016.95% SMA5019.54% SMA20046.25% Trades Volume10,628 Change1.60%
Date Action Analyst Rating Change Price Target Change
Dec-16-22Downgrade Jefferies Buy → Hold $30 → $3.60
Dec-15-22Downgrade Morgan Stanley Overweight → Equal-Weight $5
Oct-10-22Initiated Morgan Stanley Overweight $34
Oct-10-22Initiated Jefferies Buy $30
Oct-10-22Initiated Cowen Outperform
Apr-15-24 07:00PM
Mar-28-24 08:30AM
Mar-26-24 09:02PM
04:00PM Loading…
Feb-26-24 04:00PM
Jan-04-24 08:00AM
Dec-29-23 12:00PM
Dec-08-23 01:05PM
Nov-09-23 09:30AM
Oct-31-23 08:30AM
Aug-31-23 08:30AM
Aug-10-23 08:10AM
Jul-26-23 09:40AM
08:30AM Loading…
Jul-25-23 08:30AM
Jun-09-23 08:04AM
May-24-23 11:02AM
May-11-23 05:00PM
Mar-29-23 08:05AM
Dec-23-22 06:32AM
Dec-22-22 05:41AM
Dec-15-22 10:10AM
Nov-21-22 04:05PM
Nov-09-22 04:15PM
Nov-02-22 08:01AM
04:10PM Loading…
Sep-19-22 04:10PM
Sep-15-22 11:41AM
Third Harmonic Bio, Inc. develops pharmaceutical products for the treatment of allergic and immune diseases and disorders. It focuses on the development of the next wave of medicine for the treatment of allergic and inflammatory diseases. The company was founded on April 25, 2019 and is headquartered in San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Holles Natalie C.CEOApr 11 '24Option Exercise4.2013,55856,9441,232,394Apr 15 04:14 PM
Holles Natalie C.CEOApr 11 '24Sale12.1913,558165,2141,218,836Apr 15 04:14 PM
Person JulieCHIEF ADMINISTRATIVE OFFICERApr 04 '24Option Exercise4.201,1074,6491,107Apr 08 05:21 PM
Person JulieCHIEF ADMINISTRATIVE OFFICERApr 04 '24Sale10.001,10711,0700Apr 08 05:21 PM
Person JulieChief Administrative OfficerDec 05 '23Option Exercise4.2012,86354,02512,863Dec 07 04:04 PM
Conner Edward R.Chief Medical OfficerDec 05 '23Option Exercise4.204,79020,1184,790Dec 07 04:03 PM
Person JulieChief Administrative OfficerDec 05 '23Sale10.3012,863132,4840Dec 07 04:04 PM
Conner Edward R.Chief Medical OfficerDec 05 '23Sale10.034,79048,0620Dec 07 04:03 PM